Aim of the study was to compare the durability of rilpivirine (RPV)and integrase inhibitor (InSTI)-based first-line regimens in HIVinfected patients starting antiretroviral therapy (ART) with < 100,000 HIV-RNA copies/mL.
Durability of rilpivirine-and integrase inhibitor-based first-line regimens in HIV-infected patients starting antiretroviral therapy with a viral load <100.000 copies/mL: data from the ICONA Foundation Study.
G. Nunnari;G. F. Pellicanò.
2017-01-01
Abstract
Aim of the study was to compare the durability of rilpivirine (RPV)and integrase inhibitor (InSTI)-based first-line regimens in HIVinfected patients starting antiretroviral therapy (ART) with < 100,000 HIV-RNA copies/mL.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.